|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123458 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-27 11:19:35 |
|
注册时间: Date of Registration: |
2026-04-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于真实世界医疗大数据的跨人群健康轨迹演变与多场景疾病表型预测研究 |
|
Public title: |
Research on Cross-Population Health Trajectory Evolution and Multi-Scenario Disease Phenotype Prediction Based on Real-World Medical Big Data |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于真实世界医疗大数据的跨人群健康轨迹演变与多场景疾病表型预测研究 |
|
Scientific title: |
Research on Cross-Population Health Trajectory Evolution and Multi-Scenario Disease Phenotype Prediction Based on Real-World Medical Big Data |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
程舟礼 |
研究负责人: |
程舟礼 |
|
Applicant: |
chengzhouli |
Study leader: |
chengzhouli |
|
申请注册联系人电话: Applicant telephone: |
+86 21 5703 9818 |
研究负责人电话: Study leader's telephone: |
+86 21 5703 9818 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chengzhouli@fudan.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
chengzhouli@fudan.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市金山区龙航路1508号 |
研究负责人通讯地址: |
上海市金山区龙航路1508号 |
|
Applicant address: |
No. 1508 Longhang Road, Jinshan District |
Study leader's address: |
No. 1508 Longhang Road, Jinshan District |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属金山医院 |
||
|
Applicant's institution: |
Fudan University Affiliated Jinshan Hospital |
||
|
研究负责人所在单位: |
复旦大学附属金山医院 |
||
|
Affiliation of the Leader: |
Jinshan Hosptial of Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
JIEC 2026-S27 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属金山医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Approval letter of Jinshan Hospital, Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-03 00:00:00 |
||
|
伦理委员会联系人: |
王淑颖 |
||
|
Contact Name of the ethic committee: |
Wang ShuYing |
||
|
伦理委员会联系地址: |
上海市金山区龙航路1508号 |
||
|
Contact Address of the ethic committee: |
1508, Longhang Road, Jinshan District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 57039818 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
1301516297@qq.com |
|
研究实施负责(组长)单位: |
复旦大学附属金山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jinshan Hosptial of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市金山区龙航路1508号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1508, Longhang Road, Jinshan District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
基于真实世界医疗大数据的跨人群健康轨迹演变与多场景疾病表型预测研究 |
||||||||||||||||||||||
|
Source(s) of funding: |
None |
||||||||||||||||||||||
|
Target disease: |
DiabetesIschemic heart disease / heart failureCerebrovascular disease / strokeMalignant tumor (or Malignancy)HypertensionChronic liver disease / cirrhosisChronic kidney diseaseAll-cause mortality |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究为基于回顾性队列数据的预测模型外部验证与迁移学习研究。研究依托本院职业健康体检系统及住院电子病历系统,对已在国际队列(NHANES/CHARLS)中开发并初步验证的 UABA(Uncertainty-Aware Bio-Age)生物年龄评估框架进行真实世界临床验证。研究采用双队列互补设计:队列 A 来源于职业健康体检系统自2016年8月以来的全量体检记录(累计5,972 人),以基线健康人群为对象,验证 BioAge 加速对新发慢性病的预测价值;队列B来源于住院电子病历系统 2018-2020 年间的住院记录(约15,000-20,000 例),以临床患者为对象,验证 BioAge 对全因死亡的独立预后价值。SurvClock 模型所需的 20 项核心生物标志物涵盖:肝功能(白蛋白、ALP、ALT、AST、总胆红素)、肾功能(BUN、肌酐、尿酸)、代谢(空腹葡萄糖、HbA1c、BMI、腰围)、心血管(收缩压、舒张压、总胆固醇)、炎症/免疫(CRP、白细胞计数、淋巴细胞百分比)及血液系统(MCV、RDW),均广泛包含在常规体检套餐与住院基础检验中,无需额外采集生物样本。本研究将利用上述真实世界数据,建立从基线至 2025 年12月 31 日的回顾性随访队列,系统评估 UABA 框架在本院人群中的预测准确性与临床附加价值,探索生物年龄加速及跨范式分歧特征与慢性疾病发生及死亡风险的关联。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study is an external validation and transfer learning study of a predictive model based on retrospective cohort data. Leveraging our hospital’s occupational health examination system and inpatient electronic medical record system, we aim to conduct real-world clinical validation of the UABA (Uncertainty?Aware Bio?Age) biological age assessment framework, which has already been developed and preliminarily validated in international cohorts (NHANES/CHARLS). The study adopts a complementary dual?cohort design: Cohort A consists of all complete examination records from the occupational health examination system since August 2016 (cumulative n = 5,972). Focusing on healthy individuals at baseline, this cohort validates the predictive value of BioAge acceleration for incident chronic diseases. Cohort B comprises inpatient records from the electronic medical record system between 2018 and 2020 (approximately 15,000–20,000 cases). Targeting clinical patients, this cohort validates the independent prognostic value of BioAge for all?cause mortality. The 20 core biomarkers required for the SurvClock model cover: liver function (albumin, ALP, ALT, AST, total bilirubin), kidney function (BUN, creatinine, uric acid), metabolism (fasting glucose, HbA1c, BMI, waist circumference), cardiovascular parameters (systolic blood pressure, diastolic blood pressure, total cholesterol), inflammation/immunity (CRP, white blood cell count, lymphocyte percentage), and hematological system (MCV, RDW) |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 队列 A(健康人群验证与迁移学习集) 基本信息: 年龄在 18–80 周岁之间,性别不限。 时间窗:基线体检数据产生日期在 2016 年 7 月 1 日至 2020 年 12 月 31 日之间,且随访观察期≥5 年。 健康状态要求: 基线时无以下 7 项重大慢性疾病史(以 ICD-10 编码或病史记录为准):糖尿病(E10–E14)、缺血性心脏病/心衰(I20–I25, I50)、脑血管病/卒中(I60– I64)、恶性肿瘤(C00–C97)、高血压(I10–I15)、慢性肝病/肝硬化(K70–K77)、慢性肾病(N18)。 数据定量标准:必须包含以下 19 项核心生物标志物中的至少 16 项(缺失≤3 项):肝 肾功能:白蛋白、ALP、ALT、AST、总胆红素、BUN、肌酐、尿酸。代谢/心血管:空腹血糖、HbA1c、BMI、腰围、收缩压、舒张压、总胆固醇。炎症/血液:白细胞计数、淋巴细胞百分比、MCV、RDW。 2. 队列 B(全量验证与病情分层集) 基本信息: 年龄在 18-80 周岁之间,性别不限。 时间窗: 基线数据产生日期在 2018 年 1 月 1 日至 2020 年 12 月 31 日之间,且随访观察期>=5 年。 人群类别:本院健康管理中心完成体检的成人,或在上述指定临床科室(如心内科、肿瘤科等)有完整住院记录的患者。 数据定量标准:基线检验记录需包含上述 19 项核心生物标志物中的>=12 项。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Cohort A (Healthy Population Validation and Transfer Learning Set) Basic Information: Age between 18–80 years, any gender. Time Window: Baseline physical examination data generated between July 1, 2016, and December 31, 2020, with a follow-up observation period of >=5 years. Health Requirements: No history of the following 7 major chronic diseases at baseline (based on ICD-10 codes or medical history records): Diabetes (E10–E14), Ischemic Heart Disease/Heart Failure (I20–I25, I50), Cerebrovascular Disease/Stroke (I60–I64), Malignant Tumors (C00–C97), Hypertension (I10–I15), Chronic Liver Disease/Cirrhosis (K70–K77), Chronic Kidney Disease (N18). Data Quantification Criteria: Must include at least 16 out of the following 19 core biomarkers (<=3 missing items): Liver and Kidney Function: Albumin, ALP, ALT, AST, Total Bilirubin, BUN, Creatinine, Uric Acid. Metabolism/Cardiovascular: Fasting Blood Glucose, HbA1c, BMI, Waist Circumference, Systolic Blood Pressure, Diastolic Blood Pressure, Total Cholesterol. Inflammation/Blood: White Blood Cell Count, Lymphocyte Percentage, MCV, RDW. 2. Cohort B (Full Validation and Disease Stratification Set) Basic Information: Age between 18–80 years, any gender. Time Window: Baseline data generated between January 1, 2018, and December 31, 2020, with a follow-up observation period of ≥5 years. Population Category: Adults who completed physical examinations at the hospital's Health Management Center, or patients with complete hospitalization records in the specified clinical departments mentioned above (e.g., Cardiology, Oncology, etc.). Data Quantification Criteria: Baseline test records must include >= 12 of the above 19 core biomarkers. |
||||||||||||||||||||||
|
排除标准: |
1.关键数据缺失:队列 A 缺失标志物 > 3 项,或队列 B 缺失标志物 > 7 项,导致 UABA 模型无法有效估算生物年龄者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Critical missing data: more than 3 missing biomarkers in Cohort A, or more than 7 missing biomarkers in Cohort B, rendering the UABA model unable to effectively estimate biological age. Physiological/Pathological Special States: Women who are pregnant or lactating (due to physiological parameter changes that significantly deviate from the biological age baseline). Extreme Frailty: Terminal states with a life expectancy of less than 3 months (because acute and severe parameter fluctuations interfere with the identification of chronic aging characteristics). Missing Follow-up: Inability to obtain survival or outcome status before December 31, 2025, through any system (lost to follow-up). Age Limit: Baseline age <18 years or >80 years. Logically Inconsistent Data: Records with logical errors in physiological indicators (e.g., diastolic blood pressure higher than systolic blood pressure, abnormal BMI, etc.) that cannot be verified or corrected. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-04-01 00:00:00至 To 2028-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-05-01 00:00:00 至 To 2028-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究数据采用受控访问(Controlled Access)模式。经去标识化处理后的分析级数据集(非原始病历)将在论文发表后12个月内,通过国家人口健康科学数据中心或本院科研数据管理平台向合格研究者开放申请。原始生物样本及可识别信息不共享。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data in this study are managed under a controlled access model. The de-identified, analysis-ready dataset (excluding raw medical records) will be made available to qualified researchers through the National Population Health Data Center or our hospital's research data management platform within 12 months after publication of the paper. Raw biological samples and identifiable information will not be shared. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据从本院HIS系统提取后即刻去标识化(删除姓名、身份证号、病案号等直接标识符,出生日期仅保留年份)。数据存储采用AES-256加密,访问需双因素认证。符合《信息安全等级保护2.0》三级要求。数据共享前将再次进行k-匿名化处理(k≥5),确保无法反向识别个体。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were de-identified immediately after extraction from our hospital's HIS system (direct identifiers such as name, ID number, and medical record number were removed; only the year of birth was retained). Data storage employs AES-256 encryption, and access requires two-factor authentication. This complies with the Level 3 requirements of the Information Security Classified Protection 2.0. Prior to data sharing, k-anonymization (k ≥ 5) will be applied again to ensure that individuals cannot be re-identified. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |